Ten out of ten. Every young patient whose vocal cord tumor was tested at Massachusetts General Hospital — all aged 30 or under — carried high-risk strains of human papillomavirus, the same strains that drive cervical cancer (Bayan S, Glottic Carcinoma in Young Patients, 2019). Eight of those eleven young patients had never smoked.
For decades, vocal cord cancer has been described as a smoker’s disease in men over 40 — Steven Zeitels, the MGH laryngeal surgery director who led the study, has called it “almost exclusively” so. That description is breaking down, and the reason looks viral.
This article walks through what the data actually show about HPV vocal cord cancer, where current cancer society guidelines lag behind the evidence, how this viral form behaves differently from the classic smoking-driven type, and what symptoms deserve attention even in young, healthy non-smokers.
The Mass General Finding That Should Have Made Bigger News
The MGH team reviewed 353 patients treated for glottic (vocal cord) cancer between 1990 and 2018. From 1990 to mid-2004, none of the 112 patients were under 30. From mid-2004 to 2018, 11 of 241 patients were 30 or younger — three of them teenagers (Bayan S, 2019).
When the researchers tested tumor tissue from 10 of those 11 young patients, every single sample carried high-risk HPV. Only 3 of the 11 were smokers.
One detail from the paper deserves attention: one young patient had her vocal cord cancer initially misclassified as recurrent respiratory papillomatosis (RRP) — a benign HPV-related growth — and was treated with a medication that made the cancer worse, ultimately requiring partial laryngectomy. HPV-positive vocal cord cancer can look enough like a benign HPV lesion on biopsy to fool experienced clinicians.
The Trend Holds Up in a National Dataset
A 2022 analysis of the U.S. National Cancer Database — 25,029 laryngeal cancer patients between 2006 and 2015 — confirmed the pattern at scale. Among patients under 45, the rate of high-risk HPV–positive tumors was 29.9%, compared with 12.4% in older patients (Yang A, Characteristics and Outcomes of Young Patients with Laryngeal Cancer, 2022). Young patients were also more likely to be female (30.3% vs 23.3%).
Across all ages, HPV-positive laryngeal tumors were associated with lower all-cause mortality (adjusted hazard ratio 0.74). The viral version of this cancer is not just demographically different — it behaves differently.
A separate Indian cohort study found the same skew: HPV-16/18 positivity reached 40% among patients aged 31–40, versus 3.3% in patients over 50, and was higher in women (50%) than men (12.5%) (Ghosh S, High-Risk HPV Infection in Squamous Cell Carcinoma of the Larynx, 2023).
“But the American Cancer Society Says HPV Isn’t a Real Risk for Larynx Cancer”
Current American Cancer Society materials still describe HPV as a rare risk factor for laryngeal cancer, in contrast with the well-established role in oropharyngeal cancer. That framing is not wrong in absolute terms — most laryngeal cancers worldwide are still smoking- and alcohol-driven. But it underreads the trend.
Guidelines lag epidemiology by design. When historic incidence is near zero in a subgroup (under-30 vocal cord cancer), the population-attributable risk for any factor in that subgroup looks negligible until the absolute numbers grow. The MGH data and the NCDB cohort suggest those absolute numbers are growing now.
How HPV-Driven Vocal Cord Cancer Looks Different
The two pathways differ in several visible ways:
| Feature | Classic (smoking-driven) | HPV-driven |
|---|---|---|
| Typical age | 60s–70s | Teens to 30s reported |
| Sex skew | Strongly male | More female cases than expected |
| Smoking history | Yes, usually heavy | Often none |
| Histology pitfall | — | Can mimic benign RRP |
| Strain implicated | — | HPV-16 most commonly |
| Prognosis signal | Reference | Lower all-cause mortality in cohort data |
Two case reports illustrate the demographic shift. A Canadian group described an 18-year-old woman who underwent laryngectomy and adjuvant radiation for HPV-positive laryngeal squamous cell carcinoma; she has remained disease-free for 16 years. A 24-year-old woman in the same series, treated with chemoradiation, was disease-free at two years (Taboun Z, Clinical Presentation and Genomic Analysis of HPV-Related Squamous Cell Carcinoma of the Larynx in Two Young Female Patients, 2023). Both patients had no smoking or alcohol history.
Symptoms to Take Seriously, Even If You’re Young and Don’t Smoke
The hardest part of this story is that the early symptoms of vocal cord cancer are unremarkable:
- Hoarseness that lasts longer than three weeks
- Voice change with no obvious cause (no cold, no overuse)
- A persistent sensation of something in the throat
- Persistent cough or difficulty swallowing
- Painless lump in the neck
In a 25-year-old non-smoker, these symptoms get attributed almost reflexively to laryngitis, reflux, allergies, or vocal overuse. They usually are those things. But “almost reflexively” is exactly what makes the rare malignant case dangerous.
Clinical Perspective
In clinical practice, the mental model of laryngeal cancer tends to be anchored to the 60-year-old male smoker. That model is fine for the population average — but population averages are exactly what fail individual young patients with viral disease.
Two practical implications for ENT practice:
First, hoarseness lasting more than three weeks without an obvious preceding cause — like an acute respiratory infection — deserves laryngoscopy. The patient’s age, sex, and smoking status do not change that threshold. Vocal cord lesions are visible on flexible laryngoscopy in clinic; this is a five-minute exam, not a heroic intervention.
Second, the male HPV vaccine matters more than the public messaging suggests. As of May 2026, Korea’s National Immunization Program (NIP) offers free HPV vaccination to 12-year-old boys (2014 birth cohort) on a two-dose schedule at 0 and 6 months. The NIP supplies the quadrivalent vaccine; the 9-valent version remains available as a self-pay option. Both cover HPV-16, the strain most often identified in the young-patient cases discussed above. The public conversation has framed this rollout primarily around oropharyngeal (tonsil) cancer prevention in men, which is fair — that is where the strongest evidence sits. While direct long-term data on laryngeal cancer prevention are still pending, the strong biological link between high-risk HPV and glottic tumors in young patients provides a theoretical basis that the vaccine’s protective effect could extend further down the airway.
The honest summary: the smoking-driven pathway is not going away, and tobacco remains the dominant modifiable risk. But there is now a second pathway, and it does not respect the demographic assumptions that have organized laryngeal cancer screening for a century.
Key Takeaways
- High-risk HPV was detected in 10 of 10 tested vocal cord tumors from patients aged 30 or younger in a 2019 Massachusetts General Hospital cohort.
- Eight of 11 young laryngeal cancer patients in that cohort were non-smokers.
- A U.S. national database analysis found 29.9% of laryngeal cancers in patients under 45 were high-risk HPV–positive, more than double the rate in older patients.
- HPV-positive laryngeal cancer can be histologically mistaken for benign recurrent respiratory papillomatosis, creating diagnostic delay.
- Persistent hoarseness over three weeks without an obvious cause warrants laryngoscopy regardless of age, sex, or smoking status.
FAQ
Can non-smokers get laryngeal cancer?
Yes. While smoking remains the dominant risk factor for laryngeal cancer overall, a growing share of cases — particularly in patients under 45 — occur in non-smokers and appear to be driven by high-risk HPV infection. In the largest U.S. national dataset, nearly 30% of laryngeal cancers in young patients were HPV-positive.
Does the HPV vaccine prevent throat cancer?
Indirectly, yes — for the strains involved. The HPV vaccine targets HPV-16 and HPV-18, the same strains implicated in cervical cancer, oropharyngeal cancer, and the HPV-positive vocal cord cancers described in young patients. Direct evidence for laryngeal cancer prevention is still developing because these cancers take decades to emerge, but the vaccine reduces persistent infection with the implicated strains.
How is HPV transmitted to the larynx?
The leading hypothesis is oral sexual contact, the same route implicated in HPV-driven oropharyngeal (tonsil) cancers. Vertical transmission from mother to infant during birth is also a known route for benign recurrent respiratory papillomatosis caused by lower-risk HPV strains.
Is HPV-positive laryngeal cancer treatable?
Yes. Early-stage vocal cord cancer in young patients has been successfully treated with endoscopic laser approaches, and cohort data suggest HPV-positive laryngeal cancers carry better overall survival than HPV-negative ones, mirroring what is well established in oropharyngeal cancer.
Joonpyo Hong, MD is a board-certified otolaryngologist practicing in Korea. This article reflects his clinical interpretation of published research and does not constitute individual medical advice.
References
- Bayan S, Faquin WC, Zeitels SM. Glottic Carcinoma in Young Patients. Ann Otol Rhinol Laryngol. 2019;128(3 Suppl):25S-32S.
- Ghosh S, Kumar S, Chaudhary R, Guha P. High-Risk Human Papillomavirus Infection in Squamous Cell Carcinoma of the Larynx: A Study From a Tertiary Care Center in North India. Cureus. 2023;15(2):e34760.
- Taboun Z, Zeng P, Deluce J, Fung K, Barrett J, Elkadri L, Palma D, Stewart P, Cecchini MJ, Nichols A, Winquist E. Clinical Presentation and Genomic Analysis of HPV-Related Squamous Cell Carcinoma of the Larynx in Two Young Female Patients. Cureus. 2023;15(11):e48316.
- Yang A, Tanamal P, Tibbetts K, Sumer B, Blackwell JM, Schostag K, Sher D, Day A. Characteristics and outcomes of young patients with laryngeal cancer: National hospital-based retrospective cohort analysis. Head Neck. 2022;44(10):2095-2108.